This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging (DBT)

This study has been completed.
Information provided by (Responsible Party):
Siemens Medical Solutions USA - CSG Identifier:
First received: June 13, 2011
Last updated: November 18, 2016
Last verified: November 2016
The primary objective of this protocol is to collect the 2-dimensional (2D) screening and diagnostic images, and 3-dimensional (3D) Digital Breast Tomosynthesis (DBT) scans from patient mammography examinations acquired on various commercially available Full Field Digital Mammography (FFDM) systems and the Siemens Inspiration DBT system, respectively.

Condition Intervention

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Multi-center Case Collection Study to Create a Library of Images From Various Approved Full Field Digital Mammography (FFDM) Systems and 3D Images From Siemens Inspiration Digital Breast Tomosynthesis (DBT) System for Studies in Support of the Inspiration Digital Breast Tomosynthesis Approval

Resource links provided by NLM:

Further study details as provided by Siemens Medical Solutions USA - CSG:

Primary Outcome Measures:
  • Efficacy Based on the Area Under the Receiver Operating Characteristic (ROC) Curve in Breasts Analyzed With DBT as an Adjunct to FFDM vs. FFDM Alone [ Time Frame: 1 year ]
    The primary objective of this study was to demonstrate the superiority of DBT and FFDM images together in comparison to FFDM images alone with respect to the ability of readers to detect and diagnose malignant lesions. A comparison of the breast-level ROC areas was used to evaluate the superiority of DBT as an adjunct to FFDM vs. FFDM alone.

Enrollment: 764
Study Start Date: May 2011
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Mammography exam
Siemens DBT scan
DBT scan


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

All subjects enrolled into the collection study must:

  • Provide signed informed consent after receiving a verbal and written explanation of the purpose and nature of the study
  • be females, 40 years of age or older at the screening mammographic evaluation or age 30 or older presenting for a biopsy and have one of the following mammograms:

    o Normal cases at screening (BI-RADS® 1, 2 and 3):

    • have a screening mammogram that includes the four standard screening views (RCC, RMLO, LCC and LMLO), as well as have both MLO and CC DBT scans of each breast,

      o Actionable cases at screening (BI-RADS® 0, 4 or 5) with final BI-RADS® 1, 2, 3, 4 or 5:

    • have a screening mammogram with four SSVs and any clinically necessary diagnostic mammographic views, such as straight lateral projections, rolled, magnification view and spot compression views, and, both MLO and CC DBT scans of each breast plus 4 SSVs repeated at the diagnostic or biopsy visit if the screening images are unavailable or were acquired more than 45 days prior to DBT acquisition,
  • have supporting ground-truth documentation for the final BI-RADS® assessment as follows:

    • A one (1) year FFDM follow up without evidence of cancer for normal cases not undergoing biopsy
    • A six (6) or twelve (12) month FFDM follow up confirming benign status for biopsy proven benign cases
    • Pathology report for either benign or malignant biopsy finding

Exclusion Criteria:

Subjects with any of the following conditions or who have had the following procedures will be excluded from this study:

  • Pregnant women or women who believe they may be pregnant or are trying to become pregnant.
  • Mastectomy patients
  • Subjects who have had lumpectomy ≤ 5 years prior to the study entry
  • Inmates (in accordance with 45 CFR 46.306) or mentally disabled individuals
  • BI-RADS® Category 6 (e.g., for which the mammogram was performed for the purpose of planning cancer therapy)
  • BI-RADS® Category 4 or 5 without confirming pathology reports will be considered incomplete
  • Subjects with mammograms that lack the required views or with views judged to be technically inadequate will be considered incomplete and the cases will not be considered for the MRMC reader studies
  • Subjects being accrued from the screening population who know that they will not be in the United States or available for follow up mammograms in one year.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01373671

United States, Pennsylvania
Siemens Medical Solutions
Malvern, Pennsylvania, United States, 19355
Sponsors and Collaborators
Siemens Medical Solutions USA - CSG
  More Information

Responsible Party: Siemens Medical Solutions USA - CSG Identifier: NCT01373671     History of Changes
Other Study ID Numbers: SMS-SP09-01
Study First Received: June 13, 2011
Results First Received: April 27, 2016
Last Updated: November 18, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Siemens Medical Solutions USA - CSG:
Diagnostic processed this record on September 21, 2017